2. Search Result
Search Result
Results for "

Staphylococcal

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Peptides

4

Inhibitory Antibodies

4

Natural
Products

1

Recombinant Proteins

3

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107193
    Bacitracin
    3 Publications Verification

    		 Environmental Pollutants Antibiotic Bacterial PDI Infection Cancer
    Bacitracin is a polypeptide antibiotic against staphylococcal and pathogenic protozoa infections. Bacitracin inhibits cell wall biosynthesis and permeability through binding to the undecaprenyl pyrophosphate. Bacitracin inhibits macromolecular synthesis. Bacitracin is also a protein disulfide isomerase (PDI) inhibitor .
    Bacitracin
  • HY-B1455
    Clindamycin
    Maximum Cited Publications
    14 Publications Verification

    		 Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin
  • HY-B0555A
    Nafcillin sodium monohydrate
    2 Publications Verification

    		 Beta-lactamase Bacterial Antibiotic Infection
    Nafcillin sodium monohydrate, an antibiotic, is a reversible inhibitor of β-lactamase. Nafcillin sodium monohydrate can be used for the research of staphylococcal infections .
    Nafcillin sodium monohydrate
  • HY-107150
    Reproxalap

    ADX-102; NS-2

    		 PKC Caspase Neurological Disease Inflammation/Immunology
    Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis .
    Reproxalap
  • HY-113953
    Z-Asp-CH2-DCB

    		Caspase Apoptosis Inflammation/Immunology
    Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development .
    Z-Asp-CH2-DCB
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-14926
    Levonadifloxacin

    (S)-(-)-Nadifloxacin; WCK 771

    		 Antibiotic Bacterial Infection
    Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin
  • HY-115581A
    Thymidine 3',5'-diphosphate tetrasodium

    Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium

    		 Apoptosis MicroRNA Cancer
    Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5- 2H2] tyrosyl nuclease. Thymidine 3',5'-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions .
    Thymidine 3',5'-diphosphate tetrasodium
  • HY-B0555
    Nafcillin

    		Beta-lactamase Antibiotic Bacterial Infection
    Nafcillin, an antibiotic, is a reversible inhibitor of β-lactamase. Nafcillin exhibits bactericidal activity, and can be used for the research of staphylococcal infections .
    Nafcillin
  • HY-P99770
    Omodenbamab

    514-G3

    		 Bacterial Infection
    Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
    Omodenbamab
  • HY-P99309
    Pagibaximab

    BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody

    		 Bacterial Infection
    Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
    Pagibaximab
  • HY-P4211
    PSM-β

    		Bacterial Infection
    PSM-β is a active peptide , which can be isolated from Staphylococcus epidermidis. PSM-β is an analog of staphylococcal toxins, as well as a termed phenol-soluble modulin. PSM-β has bacteriostatic and poorly hemolytic properties .
    PSM-β
  • HY-163035
    EM-163

    		TNF Receptor IFNAR Inflammation/Immunology
    EM-163 is a summative BB-Loop analog. EM-163 can alleviate inflammation and prevent death from toxic shock by targeting the TIR domain of MyD88. EM-163 can be used in the study of SEB poisoning (SEB: Staphylococcal enterotoxin B) .
    EM-163
  • HY-N7118
    Clindamycin hydrochloride monohydrate

    		Bacterial Antibiotic Infection Cancer
    Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
    Clindamycin hydrochloride monohydrate
  • HY-B1455S1
    Clindamycin-13C,d3

    		Isotope-Labeled Compounds Bacterial Antibiotic Parasite Infection
    Clindamycin- 13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin-13C,d3
  • HY-B0555B
    Nafcillin sodium

    		Beta-lactamase Antibiotic Bacterial Infection
    Nafcillin sodium, an antibiotic, is a reversible inhibitor of β-lactamase. Nafcillin sodium can be used for the research of staphylococcal infections .
    Nafcillin sodium
  • HY-101726
    DuP 105

    		Bacterial Infection
    DuP 105 is an orally active oxazolidinone with activity against Gram-positive bacteria. DuP 105 protects staphylococcal and streptococcal infections in mice. DuP 105 can be used for the study of infections caused by gram-positive bacteria .
    DuP 105
  • HY-B0555BS
    Nafcillin-d5 sodium

    		Isotope-Labeled Compounds Beta-lactamase Antibiotic Infection
    Nafcillin-d5 (sodium) is the deuterium labeled Nafcillin sodium. Nafcillin sodium, an antibiotic, is a reversible inhibitor of β-lactamase. Nafcillin sodium can be used for the research of staphylococcal infections .
    Nafcillin-d5 sodium
  • HY-118917
    VX-148

    		IMPDH Inflammation/Immunology
    VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with Ki values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .
    VX-148
  • HY-B0555AR
    Nafcillin sodium monohydrate (Standard)

    		Beta-lactamase Reference Standards Bacterial Antibiotic Infection
    Nafcillin (sodium monohydrate) (Standard) is the analytical standard of Nafcillin (sodium monohydrate). This product is intended for research and analytical applications. Nafcillin sodium monohydrate, an antibiotic, is a reversible inhibitor of β-lactamase. Nafcillin sodium monohydrate can be used for the research of staphylococcal infections .
    Nafcillin sodium monohydrate (Standard)
  • HY-12824
    RNPA1000

    		Antibiotic Bacterial Infection
    RNPA1000, an antibiotic, is a potent RnpA inhibitor and inhibits RnpA-mediated cellular RNA degradation. RNPA1000 inhibits tRNA maturation with an IC50 of 175 μM. RNPA1000 displays broad-spectrum antimicrobial activities and inhibits staphylococcal and all Gram-positive bacterial pathogens activity .
    RNPA1000
  • HY-146330
    FtsZ-IN-2

    		Bacterial Infection
    FtsZ-IN-2 (Compound 19) is an inhibitor of the bacterial cell division protein FtsZ with GTPase inhibitory activity. FtsZ-IN-2 exhibits anti-staphylococcal activity with MIC values of 2 µg/ml for MSSA and MRSA .
    FtsZ-IN-2
  • HY-101829
    Sulfaproxiline

    Sulfaproxylin; Sulfaproxyline

    		 Antibiotic Bacterial Infection
    Sulfaproxyline (Sulfaproxylin; Sulfaproxyline) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate biosynthesis required for nucleic acid production. Sulfaproxyline shows antimicrobial activity primarily against Staphylococcus species and common uropathogens. Sulfaproxyline reduces bacterial growth by impairing DNA and protein synthesis. Sulfaproxyline can be used for research of staphylococcal and urinary tract infections .
    Sulfaproxiline
  • HY-173478
    OSUAB-0284

    		Topoisomerase Bacterial Antibiotic Infection
    OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
    OSUAB-0284
  • HY-143326
    Antibacterial agent 83

    		Bacterial Infection
    Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
    Antibacterial agent 83
  • HY-B1455S
    Clindamycin-d3 hydrochloride

    		Bacterial Antibiotic Parasite Infection
    Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin-d3 hydrochloride
  • HY-N7003
    28-Demethyl-β-amyrone

    28-​Norolean-​12-​en-​3-​one

    		 Bacterial Infection
    28-Demethyl-β-amyrone (28-Norolean-12-en-3-one) is one of the main triterpenes from Pistacia lentiscus var. Chia . 28-Demethyl-β-amyrone is an antitoxin and can effectively for the toxic effects of Staphylococcal enterotoxins (SEs) .
    28-Demethyl-β-amyrone
  • HY-161264
    Antiviral agent 49

    		Bacterial Infection
    Antiviral agent 49 (compound 4q) is dual antiviral and antibacterial agent. Antiviral agent 49 shows anti-enterococcus activity and anti-staphylococcal activity .
    Antiviral agent 49
  • HY-155250
    Antibacterial agent 154

    		Bacterial Infection
    Antibacterial agent 154 (compound 7) is a derivative of Fluoroqinolones and is an orally effective antibacterial agent. Antibacterial agent 154 inhibits Gram-positive and Gram-negative bacteria. Antibacterial agent 154 demonstrated in vivo efficacy in a mouse model of staphylococcal sepsis .
    Antibacterial agent 154
  • HY-14926A
    Levonadifloxacin arginine hydrate

    (S)-(-)-Nadifloxacin arginine hydrate; WCK-771A arginine hydrate

    		 Antibiotic Bacterial Infection
    Levonadifloxacin (arginine) hydrate is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin (arginine) hydrate shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin arginine hydrate
  • HY-115581
    Thymidine 3',5'-disphosphate

    Deoxythymidine 3′,5′-diphosphate; pdTp

    		 Apoptosis Cancer
    Thymidine 3',5'-disphosphate (Deoxythymidine 3′,5′-diphosphate; pdTp) is a selective small molecule inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the miRNA regulatory complex RISC subunit) and inhibits SND1 activity. Thymidine 3',5'-disphosphate exhibits anti-tumor efficacy in vivo .
    Thymidine 3',5'-disphosphate
  • HY-12824R
    RNPA1000 (Standard)

    		Reference Standards Antibiotic Bacterial Infection
    Phenyl salicylate (Standard) is the analytical standard of Phenyl salicylate. This product is intended for research and analytical applications. Phenyl salicylate (PS) has antibacterial activity when hydrolyzed in small intestine and is often used as nervous system inhibitor and intestinal preservative .
    RNPA1000 (Standard)
  • HY-14926R
    Levonadifloxacin (Standard)

    (S)-(-)-Nadifloxacin (Standard); WCK 771 (Standard)

    		 Reference Standards Antibiotic Bacterial Infection
    Levonadifloxacin (Standard) is the analytical standard of Levonadifloxacin. This product is intended for research and analytical applications. Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
    Levonadifloxacin (Standard)
  • HY-N7118R
    Clindamycin hydrochloride monohydrate (Standard)

    		Reference Standards Bacterial Antibiotic Infection Cancer
    Clindamycin (hydrochloride monohydrate) (Standard) is the analytical standard of Clindamycin (hydrochloride monohydrate). This product is intended for research and analytical applications. Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .
    Clindamycin hydrochloride monohydrate (Standard)
  • HY-147531
    Antibacterial agent 106

    		Bacterial Infection
    Antibacterial agent 106 (compound 8) is an orally active and potent antibacterial agent with antibiofilm activity. Antibacterial agent 106 shows potent antibacterial effect against multi-agent resistant (MDR)-Gram positive pathogens. Antibacterial agent 106 is highly effective in clearing 99.7% of the intracellular methicillin-resistant S. aureus (MRSA) harbored inside macrophages . Antibacterial agent 106 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Antibacterial agent 106
  • HY-B1455R
    Clindamycin (Standard)

    		Reference Standards Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin (Standard)
  • HY-P992134
    Tepsababart

    		Bacterial Infection
    Tepsababart is a humanized monoclonal antibody against staphylococcal clumping factor A, which can be used in research on antibacterial infections.
    Tepsababart
  • HY-107150R
    Reproxalap (Standard)

    ADX-102 (Standard); NS-2 (Standard)

    		 Reference Standards PKC Caspase Neurological Disease Inflammation/Immunology
    Reproxalap (Standard) (ADX-102 (Standard)) is the analytical standard of Reproxalap (HY-107150). This product is intended for research and analytical applications. Reproxalap (ADX-102) is an active aldehyde sequestering agent. Reproxalap reduces the PKCα activity. Reproxalap blocks caspase 3/7 activation. Reproxalap protects cells from the cytotoxicity of C18:0-al. Reproxalap has anti-inflammatory and pain-relieving effects. Reproxalap is used in studies of dry eye, allergic conjunctivitis, and non-infectious anterior uveitis .
    Reproxalap (Standard)
  • HY-P992091
    Nacolomab

    		Mucin Cancer
    Nacolomab is an anti-human monoclonal antibody targeting MUC1/CD227. Nacolomab can be used for the research of cancer .
    Nacolomab
  • HY-N18102
    3,4-Seco-mansumbinoic acid

    		Bacterial Infection
    3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
    3,4-Seco-mansumbinoic acid
  • HY-182417
    PD 0305970

    		Bacterial Topoisomerase Infection
    PD 0305970 is an orally active bacterial gyrase and topoisomerase inhibitor. PD 0305970 shows exceptional activity against gram-positive and fastidious organisms and more modest activity against gram-negative species. PD 0305970 shows low spontaneous resistance frequencies. PD 0305970 shows antibacterial efficacy in murine streptococcal sepsis and pneumococcal pneumonia models. PD 0305970 can be used for the research of bacterial infection .
    PD 0305970

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: